← Back

Shanghai Tofflon Science Tech

Tofflon Science and Technology Group Co., Ltd. researches, develops, produces, sells, and services pharmaceutical equipment in China and internationally. Its offerings include cell technology, complex preparation, injection, and OSD laboratory research; instruments for cell therapy and nucleic acid drugs, laboratory facilities, and table reactors; single-use technologies such as bioreactors, liquid distribution systems, sterile bags, process chromatography, and membrane filtration systems; and cryopreservation systems for seeds and biological samples, as well as freeze-thaw systems for biological stock solutions. The company also provides culture media, bioreactors, fermentation systems, cell factories, perfusion and complementary systems, preparation systems, separation and purification systems, resins, API, cleaning and sterilization, filling lines, OSD products and services, freeze-drying systems, packaging systems, isolator and inspection systems, and engineering services. Formerly known as Shanghai Tofflon Science and Technology Co., Ltd., the company was founded in 1993 and is headquartered in Shanghai, China.

Country
Price · split & dividend adjusted
News & notes moving 300171.CS
300171.CS2

Tofflon first-half net profit attributable to parent at 108 million yuan, up 134.5% year on year

Tofflon released its 2026 interim report, with first-half net profit attributable to the parent company at 108 million yuan, up 134.5% year on year. Operating revenue was 2.53 billion yuan, up 4.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 94.44 million yuan, up 270.7% year on year. Net operating cash flow was 91.1 million yuan, down 67.0% year on year. Earnings per share were 0.1406 yuan. In the second quarter, operating revenue was 1.43 billion yuan, up 10.5% year on year, and net profit attributable to the parent was 80.16 million yuan, up 210.9% year on year. As of the end of the second quarter, total assets were 13.613 billion yuan, up 0.8% from the end of the previous year, and net assets attributable to the parent were 7.972 billion yuan, up 0.5% from the end of the previous year. The company noted in the interim report that its internationalization strategy made progress, with international operating revenue reaching 1.04 billion yuan, up 29.24% year on year. The gross margin for domestic business was 25.81%, up 6.36 percentage points from the same period last year. The main risks the company faces include industry competition, economic cycle fluctuations, fundraising and investment projects, external mergers and acquisitions, internal management, human resources, and exchange rate risks, and it has taken corresponding measures to address them.
财中社·23dRead more →
300171.CS

Tofflon Plans Cash Dividend of 0.66 Yuan per 10 Shares

Tofflon announced on August 27 that it plans to distribute a cash dividend of 0.66 yuan, tax included, per 10 shares to all shareholders, with an estimated total payout of 50.22 million yuan. In the first half of 2026, Tofflon achieved revenue of 2.535 billion yuan and net profit attributable to the parent company of 108 million yuan.
财中社·23dRead more →